Literature DB >> 24557476

Red fist and muscle weakness with a rare complication.

Iris van Groeningen1, Joyce Arnoldus, Roos Perenboom, Alexandre Voskuyl.   

Abstract

A 64-year-old man was referred to our hospital, for a second opinion, with fever, skin lesions and general muscle pain. He has been treated in another hospital with antibiotics on suspicion of erysipelas. A week later skin lesions developed on the metacarpophalangeal and proximal carpophalangeal joints of the hands and nose. His mobility was impaired due to muscle pain and muscle weakness. He also showed proximal muscle atrophy and most importantly a typical heliotrope rash in the eyes. Based on these clinical observations, the most likely diagnosis was dermatomyositis. The diagnosis was confirmed by the presence of increased serum creatine kinase levels and abnormalities in skin and muscle biopsy. Prednisone (70 mg/kg) was initiated, but after 19 days the patient developed a Pneumocystis jiroveci pneumonia. He died of respiratory failure a few days later.

Entities:  

Mesh:

Year:  2014        PMID: 24557476      PMCID: PMC3931948          DOI: 10.1136/bcr-2013-202457

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

1.  PCP chemoprophylaxis is essential for lymphopenic dermatomyositis patients treated with immunomodulators.

Authors:  Petros Efthimiou; Hiren Pokharna; Manil Kukar; Karen Hennessey
Journal:  Muscle Nerve       Date:  2011-04-12       Impact factor: 3.217

2.  Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis.

Authors:  H Bachelez; B Schremmer; J Cadranel; F Mouly; C Sarfati; F Agbalika; B Schlemmer; C M Mayaud; L Dubertret
Journal:  Arch Intern Med       Date:  1997-07-14

3.  Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study.

Authors:  R Buchbinder; A Forbes; S Hall; X Dennett; G Giles
Journal:  Ann Intern Med       Date:  2001-06-19       Impact factor: 25.391

Review 4.  Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome.

Authors:  Kent A Sepkowitz
Journal:  Clin Infect Dis       Date:  2002-03-21       Impact factor: 9.079

5.  Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality.

Authors:  M M Ward; F Donald
Journal:  Arthritis Rheum       Date:  1999-04

6.  Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases.

Authors:  B Godeau; V Coutant-Perronne; D Le Thi Huong; L Guillevin; G Magadur; M De Bandt; S Dellion; J Rossert; G Rostoker; J C Piette
Journal:  J Rheumatol       Date:  1994-02       Impact factor: 4.666

7.  Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus.

Authors:  A Kadoya; J Okada; Y Iikuni; H Kondo
Journal:  J Rheumatol       Date:  1996-07       Impact factor: 4.666

8.  Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark.

Authors:  W H Chow; G Gridley; L Mellemkjaer; J K McLaughlin; J H Olsen; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1995-01       Impact factor: 2.506

9.  Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy.

Authors:  M M Joffe; L A Love; R L Leff; D D Fraser; I N Targoff; J E Hicks; P H Plotz; F W Miller
Journal:  Am J Med       Date:  1993-04       Impact factor: 4.965

10.  Audit of pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period.

Authors:  K Meuli; P Chapman; J O'Donnell; C Frampton; L Stamp
Journal:  Intern Med J       Date:  2007-05-21       Impact factor: 2.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.